

Long-term intake of Korean red ginseng destroys HIV-1 *nef* gene: a possibility as therapeutic vaccine 2004. 5. 11.

Young Keol Cho, Jiyeon Lim, Yousun Jung, Heungsup Sung

Department of Microbiology, University of Ulsan College of Medicine, 388-1 Poongnap-dong, Songpa-ku, Seoul 138-040, Korea

Introduction of highly active antiretroviral drug therapy (HAART) has given much hope to human immunodeficiency virus-1 (HIV-1) infected patients (1,2). However, this therapy alone cannot eradicate the virus in human body because of long-lasting provirus in the reservoirs (3-5). Although IL-2 has been tried into AIDS therapy as combination therapy with HAART, it has many limitations to continuous application. Thus, a new modality is required for more effective AIDS therapy.

We have obtained various beneficial effects by KRG-intake since 1991 (6-9). Among the 90 patients who were previously determined for HLA-class I, we selected all living patients who have been checked for CD4 T cell over 10 years and have not been treated with antiretroviral therapy. They were 31 (The number corresponds to about 10% out of all 311 HIV-1 patients diagnosed up to October 1993 in Korea). We divided them into 2 groups according to the amount of KRG-intake we have supplied since 1991; group A with consistent and significant KRG-intake and group B with a little or no KRG-intake. Groups A and B were treated with KRG (7,971±3,853g) for 135±14 months and with KRG (992±1069g) for 125±19 months between the first and last CD4 T cell counting. Although CD4 T cell count significantly decreased at 2 groups ($P < 0.001$), the degree of decrease at group A (155/ul; annual decrease of 14/ul) was greatly less than that (456/ul; annual decrease of 44/ul) at group B. Our data in group B underestimates the rate of decrease in CD4 T cell in our cohort because the patients who had rapidly progressed to AIDS and died within 10 years after diagnosis were not included in the present study. On the other hand, HIV-1 RNA copy was lower at group A than B ($P < 0.01$) and the number of patients with protective HLA alleles was higher than at group B ($P < 0.05$).

HIV-1 *nef* is essential gene for the progression to AIDS. Gross deletion in the *nef* gene (>more than 40 bp) has been rarely reported in LTNPs. Rhodes et al reported that the patients who revealed gross deletion was 3 out of 70 LTNPs (4.3%)(10). Thus, to investigate whether there is an association between slow progression by KRG-intake and gross deletion in the *nef*, we have determined *nef* gene sequences (about 630 bp)

from 138 patients. In some patients, it has been determined over 10 years. In the present study, we present data from 115 excluding 23 hemophiliacs originating from a few common sources. The 115 patients are divided into 77 subtype B HIV-1 and 38 non-subtype B HIV-1 and also divided into 2 groups according to KRG-intake or not. Gross deletion was detected 35.1% (27/77) in patients with subtype B, whereas it was detected 15.8% (6/38) in patients with non-subtype B.

In subtype B, there was a strong causal relationship between KRG-intake and gross deletion (2/24 versus 25/53; $P < 0.001$). Nature of gross deletion in the present study greatly differs from previous studies; in particular, the deletion extended beyond nef gene in 12 out of the 27 patients. Fourteen patients showed wild type nef only at baseline and significant period, and then revealed deleted one. First detection of gross deletion was 22 months (median)(range; 4-128) after KRG-intake. Except 2 sequences with Δ of 41 bp and 94 bp, size of deletion was larger than 100 bp (11). Regarding progression rate to AIDS, gross deletion was detected in 10 (76.9%) out of 13 LTNPs and 4 (30.8%) out of 13 NG ($P < 0.05$), indicating a strong association between slow progression and gross deletion. In contrast, there was no such causal relationship in patients with non-subtype B. These data show that long-term intake of KRG destroys HIV-1 virus in vivo and thereby significantly delays progression to AIDS. This finding suggests that KRG-intake have played as therapeutic vaccine.

References

1. Ho DD. et al., Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection *Nature* 373, 123-126 (1995).
2. Wei, X et al. Viral dynamics in human immunodeficiency virus 1 infection. *Nature* 373, 117-122 (1995).
3. Chun TW. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. *Proc Natl Acad Sci USA* 94, 13193-13197(1997).
4. Finzi D et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science* 278, 1295-1300 (1997).
5. Wong JK. et al. Quantification of replication-competent HIV despite prolonged suppression of plasma viremia. *Science* 278. 1291-1295 (1997)
6. Cho YK, Sung HS, Lee HJ, Joo CH, Cho GJ; Long-term intake of Korean red ginseng in HIV-1 infected patients:development of resistance mutation to zidovudine is delayed. *Int. Immunopharmacology*. 2001 1(7):1295-1305.
7. Cho YK, Sung H, Ann SH, Bae IG, June Hee Woo, Won YH, Kim DG, Kang MW;

Frequency of mutations conferring resistance to nucleoside reverse transcriptase inhibitors in HIV-1 infected patients in Korea. *J Clinical Microbiology* 40(4):1319-1325, 2002.

8. Cho YK, Yoo K Kim, Inchul Lee, Min H Choi, Yung O Shin: The effect of Korean red ginseng (KRG), zidovudine, and the combination of KRG and ZDV on HIV-infected individuals. *J Korean Soc. Microbiol.* 31(2):353-360, 1996.

9. Cho YK, Lee HJ, Kim YB, Oh WI, Kim YK: Sequence analysis of C2/V3 region of human immunodeficiency virus type 1 gp120 and its correlation with clinical significance; the effect of long-term intake of Korean red ginseng on env gene variation. *J Korean Soc. Microbiol* 1997, 32(5):611-623.

10. Rhodes DI, Ashton L, Solomon A, Carr A, Cooper D, Kaldor J, Deacon N. Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression. Australian Long-Term Nonprogressor Study Group. *J Virol.* 2000, 74(22):10581-8.

11. Cho YK; Effects of Korean red ginseng on high frequency of gross deletion in the nef gene and progression rate, Keystone symposia, abstract no. 139, in *Molecular mechanisms of HIV pathogenesis (X7)*. Whistler Canada, April 11-18, 2004.

연락주소;

서울시 송파구 풍납동 388-1 서울아산병원내 울산의대 미생물학교실
조영걸, 전화 및 팩스 2-3010-4283, E-mail:ykcho2@amc.seoul.kr

본 과제는 한국인삼공사에서 지원한 연구비와 시료에 의거 수행하였음.